Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Vaccine Contract Manufacturing Market Expected To Reach $6.46 Billion By 2030 At 10.9% CAGR
The market for vaccine contract manufacturing experienced robust expansion recently. Projections indicate a rise from $3.88 billion in 2025 to $4.27 billion in 2026, reflecting a compound annual growth rate of 10.0%. This upward trajectory during the past period is largely due to the broader scope of worldwide vaccination initiatives, the escalating intricacy involved in manufacturing vaccines, the increasing dependence on expert contract manufacturing firms, the proliferation of collaborative efforts between public and private sectors for vaccine development, and the establishment of significant vaccine production infrastructure.
Regarding the vaccine contract manufacturing sector, a significant increase in its market value is anticipated over the upcoming years, projected to reach $6.46 billion by the year 2030, demonstrating a compound annual growth rate of 10.9%. This upward trajectory during the projected timeframe is fueled by several key factors, including the escalating need for swift vaccine production scaling, augmented investment flowing into mRNA and innovative vaccine technologies, the broadening of commercial-scale manufacturing operations, a heightened emphasis on nations achieving their own vaccine production independence, and the integration of sophisticated bioprocessing techniques. Furthermore, prominent developments expected within this period encompass a greater tendency for vaccine production to be contracted out, a surge in the requirement for adaptable manufacturing capacities, extensions in the services offered for filling and finishing vaccines, a stronger concentration on manufacturing processes that adhere to regulatory standards, and a more widespread adoption of disposable bioprocessing equipment.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12216&type=smp
Vaccine Contract Manufacturing Market Industry Drivers: What Is Driving Revenue Growth?
The increasing prevalence of infectious diseases globally is anticipated to fuel the expansion of the vaccine contract manufacturing sector. Infectious diseases are conditions caused by disease-causing organisms including bacteria, viruses, fungi, or parasites, and their outbreaks, such as those involving influenza, measles, or novel viruses, necessitate a rapid increase in vaccine production to curb further transmission. Contract manufacturers possess the capability to swiftly enhance their output in reaction to these public health emergencies. Illustratively, data from the World Health Organization, a global health agency headquartered in Switzerland, indicated that in October 2024, roughly 8.2 million individuals received new tuberculosis diagnoses in 2023, an increase from approximately 7.5 million in 2022, positioning tuberculosis as the foremost fatal infectious disease, underscoring how the escalating global incidence of infectious diseases is a primary driver for the vaccine contract manufacturing market’s growth.
Vaccine Contract Manufacturing Market Segment Landscape And Growth Potential
The vaccine contract manufacturing market covered in this report is segmented –
1) By Service Type: Fill-Finish, Bulk Product
2) By Vaccine Type: Inactivated Vaccines, Live-Attenuated Vaccines, RNA (Ribonucleic Acid) Vaccines, Subunit Vaccines, Toxoid-Based Vaccines
3) By Process: Downstream, Upstream
4) By Scale Of Operation: Preclinical, Clinical, Commercial
5) By End-Use: Human Use, Veterinary
Subsegments:
1) By Fill-Finish: Aseptic Fill-Finish, Lyophilization, Vial Filling, Syringe Filling
2) By Bulk Product: Cell Culture, Microbial Fermentation, Antigen Production, Buffer Preparation
#Vaccine Contract Manufacturing Market Growth Trends: What Is Influencing The Future Outlook?
Leading entities within the vaccine contract manufacturing sector are prioritizing the inauguration of new production facilities to solidify their market standing. The establishment of these vaccine contract manufacturing sites signifies the creation of dedicated operational bases for producing vaccines under contract. As an illustration, WuXi Vaccines, a Chinese contract development and manufacturing organization renowned for its vaccine expertise, inaugurated its inaugural independent vaccine CDMO facility in Suzhou, China, in September 2023. This strategic expansion significantly boosts the company’s capacity for both the manufacturing of the core vaccine components and the final drug product. Consequently, WuXi Vaccines now provides an all-encompassing suite of services that span various vaccine types, encompassing process refinement, drug product formulation, and the manufacturing of clinical-stage drug substances alongside sterile drug products in small to medium volumes. This newly commissioned independent facility amplifies WuXi Vaccines’ potential to participate in vaccine creation and production, thereby assuming a crucial role in propelling global health advancements.
Vaccine Contract Manufacturing Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the vaccine contract manufacturing market are Pfizer Inc, Johnson & Johnson, AbbVie Inc., Sanofi, GlaxoSmithKline, Merck KGaA, Moderna, BioNTech, GSK Vaccines, AstraZeneca PLC, Ajinomoto Co. Inc., Lonza Group AG, Catalent Inc., Charles River Laboratories International Inc., Serum Institute of India Pvt. Ltd, Samsung Biologics, WuXi Biologics, Novavax, Sinovac Biotech, Emergent BioSolutions Inc., Bio Farma, Hualan Biological Engineering, BioMARC, Bavarian Nordic A/S, AGC Biologics, IDT Biologika GmbH, Bharat Biotech, Goodwin Biotechnology Inc., Biofabri S.L
Access The Complete Vaccine Contract Manufacturing Market Report:
Vaccine Contract Manufacturing Market Regional Distribution: Which Areas Drive Market Expansion?
North Americawas the largest region in the vaccine contract manufacturing market in 2025. Asia-Pacificis expected to be the fastest-growing region in the vaccine contract manufacturing market report forecast period. The regions covered in the vaccine contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
